Title
Pact for vaccine development
VATIS UPDATE Part
Article body
Takeda Pharmaceutical Company, Japan, and Biological E Ltd (BE), India, have signed two licensing agreements for development and delivery of affordable combination vaccines for low and middle-income countries. According to BE, Takeda will transfer to BE its existing measles and acellular pertussis vaccine bulk production technology.
The transfer also will include the provision of technical services such as support in infrastructure review, training for production and quality control, assistance in process development, preclinical study design, and production of clinical batch and the first commercial batches. BE will commercialise the vaccine in India, China and low and middle-income countries where large, unmet public health needs exist.